Tissue microarray (TMA) is a recipient paraffin block that comprises thousands of separate tissue centers assembled in array fashion to allow multiplex histological analysis. These TMAs allow a quick, cost-effective, high through-put examination of thousands of molecular markers at nucleic acids or protein level. TMA is the latest advancement in the field of pathology. Different sorts of tumors at different phases of disease progression can also be studied at a single stage, in identical conditions in less labor-intensive and cost-effective ways.

The market for tissue microarray treatment is growing extensively. It is a practical and efficient tool for high-throughput molecular analysis of tissues that help to identify new diagnostic and prognostic markers. It also targets human cancers and has a range of potential applications in basic research, prognostic oncology, and drug discovery. The growing need for targeted treatments for various chronic diseases such as cancer, genetic diseases, and others has boosted the growth of the market

Increasing application in drug discovery is one of the major factors driving the market growth. During drug research and development, the risk of product failure is high. Moreover, advancement in molecular methods have massively simplified the discovery of potential molecular targets for gene-specific therapy. Application in drug discovery has generated a massive demand for such supposed targets and to meet such demand human tissue analysis is needed. Nevertheless, the need for analysis of large numbers of well-characterized human tissues constitutes a major role in the drug discovery and development. Earlier, tissue analysis used to be done in slide-by-slide manner, which was time consuming, expensive, and difficult to operate.

Increasing prevalence of cancer is one of the important factors that drives the growth of the tissue microarray market. According to the American Cancer Society, in 2017, about 1 in 8 the U.S. women (about 12%) predicted to develop invasive breast cancer over the course of her lifetime. In 2017, an estimated 252,710 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 63,410 new cases of non-invasive (in situ) breast cancer.

However, tissue microarray may not be fruitful for heterogeneous cancers, which may hamper the market growth over the review period.

The Americas dominates the global tissue microarray market owing to the presence of strong economic condition, huge development in healthcare domain, and focus of research institutions on updating technology for new and advanced diagnosis and treatment methods. Moreover, advanced hospitals infrastructures, availability of skilled healthcare professional are boosting the growth of the market.

Europe holds the second position in the market on the basis of increasing emphasis on rapid diagnosis and treatment of cancer, and infectious diseases, changing lifestyle, increasing prevalence of cancer among geriatric population. As per Organization for Economic Co-operation and Development (OECD), the share of GDP to health spending in Germany was 11.0% in 2013, which was 10.8% in 2012, thus this factor also drives the growth of the market in this region. All these factors will drive the market growth in Europe.

Asia Pacific is the fastest growing market owing to more number of developing nations present in this region, for instance, countries like India and china are encouraging the growth of the healthcare domain. Furthermore, increasing patient population from cancer in developing countries will directly increase the demand for various diagnosis & treatment methods and it will boost the growth of the market.

The Middle East & Africa is expected to hold the least market share due to less availability of medical facilities, and less development in the healthcare domain. However, countries such as Qatar and Kuwait are focusing more in healthcare domain and developing medical facilities, which will boost the market growth in this region.

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.